Please login to the form below

Not currently logged in
Email:
Password:

Cornerstone Therapeutics

This page shows the latest Cornerstone Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Chiesi hits the acquisition trail again

Chiesi hits the acquisition trail again

company Cornerstone Therapeutics. ... The value of the deal is around $107m and all in all values Cornerstone at some $255m.

Latest news

  • Biologics buoyant

    Three of the deals, with Amplimmune, FivePrime Therapeutics and Genmab, focus on biologics. ... 84+. Cornerstone Therapeutics/Targacept . Alpha-7 and other nicotinic receptor targeting compounds. Preclinical .

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... Cornerstone Therapeutics,  respectively.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics